Case Studies

1. Virtual Global RWE Workshop – Co-Creation

Client: Top 10 Pharmaceutical Company

Challenge:

A top 10 global biopharmaceutical company aimed to convene a virtual workshop on Real-World Evidence (RWE) with external stakeholders, including significant participation from emerging markets. The event needed to deliver scientific alignment under tight timelines while ensuring regulatory and compliance integrity.

Our Role:

• Co-led the end-to-end coordination of the global virtual event, in collaboration with the company and its agency partner
• Ensured seamless experience for speakers and participants across time zones, including many from emerging markets
• Managed content review and compliance oversight to meet internal and external standards
• Facilitated structured discussions to align on the global RWE strategy.

Impact:

• Delivered a compliant, highly engaging virtual event within 3 months of initiation
• Led and ensured alignment across global teams and country affiliates
• Supported meeting outputs to be presented to upper management and internal stakeholders, including a program highlights video, and post-meeting outputs for local country affiliate utilization 

2. Companion Diagnostic Readiness – Launch Preparation for Oncology Asset

Client: Top 10 Pharmaceutical Company

Challenge:

A large biopharmaceutical company preparing to launch a targeted oncology therapy required assessing the access environment for companion diagnostics(CDx). It also required readiness to integrate a CDx access plan across key global markets. Given the varied market understanding and preparation regarding testing infrastructure, regulatory pathways, and clinical adoption, an algorithm for integrating a CDx access strategy was a critical success factor for asset launch success.

Our Role:

• Prepare an algorithm to assess country dynamics and build archetypes for rapid landscape assessment across global markets.
• Mapped testing types to be used
• Developed strategic recommendations to optimize CDx rollout in sync with drug launch.

Impact:

• Enabled alignment between global medical, commercial, and access teams
• Identified country-level gaps and mitigation steps
• Informed development of a CDx access strategic plan

3. Early Access Strategy – Oncology Launch Planning

Client: Top 10 Pharmaceutical Company

Challenge:

A global biopharmaceutical company requested expert support to define a fit-for-purpose early access program (EAP) for an innovative oncology asset. This included understanding possible demand and a strategy to address patient needs before regulatory approval and reimbursement.

Our Role:

• Defined various types of EAPs to align communication between different countries
• Developed a tiered EAP strategy integrating ethical, logistical, and reputational considerations
• Aligned global and local cross-functional teams on risk-benefit tradeoffs

Impact:

• Delivered early access readiness roadmap

– Strengthened internal stakeholder trust through a clear and compliant EAP plan
– Ensured that patient needs are addressed when early access is required

4. Oncology Asset Value Assessment

Client: Private Equity

Challenge:

A healthcare division of a private equity firm was evaluating the acquisition of oncology assets from a biopharmaceutical company. A rapid, evidence-based valuation of the opportunity and forecast model was required.

Our Role:

• Conducted scientific and commercial due diligence on multiple oncology assets
• Built dynamic forecast models incorporating market evolution, clinical potential, and competitive landscape
• Provided risk-adjusted value estimates to guide investment decisions

Impact:

• Delivered actionable insights enabling refinement of the asset offer
• The project resulted in a positive investment committee endorsement
• Enhanced credibility of the investor team with biotech sellers and co-investors